Owens & Minor price target raised to $28 from $22 at UBS

UBS raised the firm’s price target on Owens & Minor to $28 from $22 and keeps a Buy rating on the shares. Owens & Minor plans to expand Patient Direct and reach $5B in revenues, and UBS tells investors that the story becomes more about the Patient Direct segment and less about the legacy business and destocking.